- Home
- MQ vs KRSA Comparison
MQ vs KRSA Comparison
Compare MQ & KRSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MQ | KRSA |
|---|---|---|
| Founded | 2010 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MQ | KRSA |
|---|---|---|
| Price | $18.66 | $30.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $20.70 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 771.8K | 150.4K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $624,884,000.00 | $2,074,000.00 |
| Revenue This Year | $12.02 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.25 | 3.70 |
| 52 Week Low | $3.70 | $29.03 |
| 52 Week High | $19.40 | $37.27 |
Technical Indicators
Market Signals| Indicator | MQ | KRSA |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 46.00 |
| Support Level | $15.28 | $29.67 |
| Resistance Level | $18.69 | $35.04 |
| Average True Range (ATR) | 0.69 | 2.19 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 62.77 | 29.84 |
Price Performance
Historical ComparisonAbout MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About KRSA Korsana Biosciences Inc. Common Stock
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.